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ABSTRACT
Objective To examine the influence of previous
antiplatelet or anticoagulant therapy on subsequent
stroke mortality at different time points up to 1 year post
stroke.
Design Data were examined from a hospital register
collected over 5 years (2004e2008).
Setting A single large university hospital.
Participants Every adult (18+ years) admitted with an
acute stroke.
Main outcome measures Mortality risks at 7, 30, 60,
90 and 365 days were assessed using logistic regression
following ischaemic and haemorrhagic stroke, adjusting
for age, gender, premorbid Rankin and stroke type.
Results 3308 patients with first or recurrent stroke were
included (53% women, mean age 77.7611.5 years, 86%
ischaemic stroke). One-year mortality was 35.2% (999)
for ischaemic stroke and 48.3% (227) for haemorrhagic
stroke. Compared with no previous therapy, the mortality
following ischaemic stroke for those already receiving
antiplatelets or anticoagulants was not associated with
increased mortality at any time points up to 1 year after
presentation in the fully adjusted model. However,
patients with haemorrhagic stroke had a worse
prognosis at all time points after standard risk factor
adjustment. For patients who used aspirin or warfarin
prior to haemorrhagic stroke compared with no use, ORs
(95% CIs) were 1.31 (0.64 to 2.68) and 2.91 (1.23 to
6.89) for 7 days, 2.36 (1.18 to 4.71) and 2.37 (1.00 to
5.61) for 30 days, 2.18 (1.10 to 4.29) and 2.86 (1.20
to 6.84) for 60 days, 2.56 (1.27 to 5.13) and 2.82 (1.16
to 6.86) for 90 days and 1.67 (0.89 to 3.12) and 2.44
(1.06 to 5.62) for 365 days.
Conclusions Prior antiplatelet or anticoagulant use was
associated with increased mortality following HS but not
IS after adjustment for common factors associated with
a poor prognosis. The reasons for this poor prognosis and
potential therapeutic options need exploring in future
studies.
INTRODUCTION
Antiplatelet/anticoagulant (AP/AC) agents are
frequently prescribed for people at risk of stroke
and other cardiovascular diseases in primary and
secondary prevention. Good evidence exists for the
use of these agents in secondary prevention
following ischaemic stroke1 2 but their use in
primary prevention especially for AP agents
remains controversial.3 4
Apart from warfarin use in atrial ﬁbrillation, the
effect of these agents prior to stroke on subsequent
survival is not well known. To date, conﬂicting
evidence exists regarding the inﬂuence of premorbid
medications on outcomes in patients with
ischaemic stroke.5 6 Similarly there is mixed
evidence regarding the impact of prior AP agents in
patients with haemorrhagic stroke. Foerch et al,
using data from the German Stroke Register,
showed that pretreatment with AP agents was
not independently associated with unfavourable
outcomes,7 although a recent meta-analysis
suggested it was associated with an increase in
mortality but not poor functional outcomes.8
Whether AP/AC use prior to stroke is associated
with an increased or a decreased mortality risk and
whether this is inﬂuenced by the time from stroke
onset has not been previously examined. In this
study, we investigate the effects on mortality at 7,
30, 60, 90 and 365 days post stroke in relation to
previous AP/AC therapy for ischaemic and
haemorrhagic stroke.
METHODS
The study sample consists of consecutive stroke
patients admitted to a single large university
hospital with a catchment population of approxi-
mately 750 000 in Central Norfolk, UK between
January 2004 and November 2008. The study
participants were drawn from the comprehensive
Norfolk and Norwich University Hospital Stroke
Register, which has been previously described.9
Brieﬂy, the Norfolk and Norwich Hospital Stroke
Register was established in late 1996 based on the
European Basic Stroke Register and collects infor-
mation on every adult (18+ years) admitted with
an acute stroke. Institutional approval was
obtained from the Norfolk and Norwich Hospital
Trust Research and Development Committee.
Data collection
Data were collected prospectively by specialist
stroke nurses or doctors to ascertain variables
such as age, gender, type of stroke based on CT
(ischaemic or haemorrhagic), premorbid Rankin
score (0e5), Oxfordshire Community Stroke
Project (OCSP) Classiﬁcation and mortality.
Haemorrhagic transformation of ischaemic stroke
was classiﬁed as ischaemic stroke and subarachnoid
haemorrhages were excluded. All stroke cases were
veriﬁed by experienced stroke physicians. Informa-
tion on prior AP/AC use was obtained from the
medication list of the patient on admission. For
each patient, when admitted the premorbid (pre-
stroke) Rankin score (see footnote to table 1), as
modiﬁed by the UK transient ischaemic attack
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investigators,10 was ascertained from nursing and medical
records. For this study, data were included up to November 2008
with 1-year follow-up data ascertained in November 2009. Prior
AP/AC use was recorded since January 2004 and any stroke
patients admitted up to that time point were excluded.
Outcome
The outcome of interest was mortality in the short (7 and
30 days), medium (60 and 90 days) and long term (365 days)
post admission for the index stroke admission. Whether patients
were dead or alive at these time points was ascertained using the
hospital Patient Administrative System (PAS), which has been
previously described.11 Because nearly 100% of the population in
the UK is registered with the National Health Service (NHS),
the PAS which records the healthcare episodes is a valid and
reliable way of determining mortality. Brieﬂy, PAS records the
movement of patients and whether a patient is alive or dead at
any given time by having a system that enables local general
practitioners to report deaths that occur in the community.
Statistical analysis
Data were analysed using STATA V.10.0 (2009, StataCorp).
KaplaneMeier (KM) curves (unadjusted) were drawn for
mortality based on different prior AP/AC medication use.
Logistic regression was used rather than survival analysis
methods because there were no competing risks as we analysed
all-cause mortality and had a follow-up rate of 100% for at least
a year, so there was no censoring.
Risk estimates (ORs) were determined using four different
models: ﬁrst unadjusted, second adjusting for age, the square of
age and gender, third additionally adjusting for premorbid
Rankin score, and ﬁnally also adjusting for Oxfordshire
Community Stroke Project (OSCP) classiﬁcation. Age was
modelled as a quadratic term because the ageemortality rela-
tionship was nonlinear. Because discharge AP/AC medication
depends on the admission drug therapy and patients’ condition
(eg, newly diagnosed atrial ﬁbrillation), we repeated the analyses
by additionally adjusting for discharge AP/AC use for those who
were discharged alive after ischaemic stroke.
RESULTS
A total of 3308 patients were included in this study. Table 1
shows the characteristics of these patients by different pre-
stroke medication. The majority (51%) of patients were not on
any AP/AC treatment prior to stroke. Among those who were
on AP/AC medication, aspirin was the most commonly used
therapy (34%). Of the study population, 53% were women, 86%
presented with ischaemic stroke and 14% presented with
haemorrhagic stroke.
Table 2 shows patient mortality for the various follow-up
time points. The highest mortality following ischaemic stroke
was observed between 90 and 365 days post ictus. In contrast,
for haemorrhagic stroke the highest mortality occurred in the
ﬁrst 7 days following the incident stroke. The cumulative
mortality was signiﬁcantly lower for patients with ischaemic
stroke compared with haemorrhagic stroke at 1 year. A log-rank
test for equality of the survivor functions showed a highly
signiﬁcant difference between the groups over 365 days of
follow-up.
The KeM survival curves for the patients who were receiving
different AP/AC regimes (warfarin in 7% of cases) are shown in
ﬁgures 1 and 2 for haemorrhagic and ischaemic stroke, respec-
tively. For haemorrhagic stroke, prior aspirin or warfarin use was
associated with reduced survival compared with no prior aspirin
Table 1 Sample characteristics by type of prior antiplatelet and anticoagulant use
Total None Aspirin Aspirin plus dipyridamole Clopidogrel Warfarin
Patients 3308 1763 (53) 1140 (34) 94 (3) 74 (2) 237 (7)
Age group
<65 447 (14) 317 (18) 98 (9) 6 (6) 10 (14) 16 (7)
65e74 653 (20) 361 (20) 215 (19) 13 (14) 18 (24) 46 (19)
75e84 1300 (39) 641 (36) 455 (40) 53 (56) 29 (39) 134 (51)
>85 908 (27) 444 (27) 372 (33) 22 (23) 17 (23) 53 (22)
Gender
Men 1570 (47) 791 (45) 562 (49) 51 (54) 34 (46) 132 (56)
Women 1738 (53) 972 (55) 578 (51) 43 (46) 40 (54) 105 (44)
Premorbid Rankin*
0 2161 (70) 1206 (73) 706 (66) 49 (57) 48 (70) 152 (70)
1 236 (8) 110 (7) 81 (8) 16 (19) 5 (7) 24 (11)
2 216 (7) 107 (7) 84 (8) 5 (6) 6 (9) 14 (6)
3 298 (10) 139 (8) 127 (12) 10 (12) 7 (10) 15 (7)
4 134 (4) 63 (4) 53 (5) 4 (5) 2 (3) 12 (5.5)
5 43 (1) 17 (1) 23 (2) 2 (2) 0 (0) 1 (0)
Ischaemic stroke 2838 (86) 1499 (85) 1009 (89) 86 (91) 63 (84) 181 (70)
Haemorrhagic stroke 470 (14) 264 (15) 131 (11) 8 (9) 11 (15) 56 (21)
OCSP classification
TACS 809 (26) 366 (22) 259 (24) 28 (32) 17 (24) 58 (27)
PACS 1053 (34) 577 (35) 359 (33) 26 (30) 28 (39) 63 (29)
POCS 489 (16) 430 (26) 165 (15) 23 (26) 12 (17) 34 (16)
LACS 721 (23) 267 (16) 366 (22) 11 (13) 14 (20) 54 (25)
Unspecified 49 (2) 27 (2) 27 (1) 0 (0) 0 (0) 6 (3)
Data presented are number (%).
*Premorbid Rankin: 0: no symptoms at all; 1: no significant disability despite symptoms, able to carry out all usual duties and activities; 2: slight disability; unable to carry out all previous
activities but able to look after own affairs without assistance; 3: moderate disability, requiring some help, but able to walk without assistance; 4: moderately severe disability, unable to walk
without assistance and unable to attend to own bodily needs without assistance; 5: severe disability, bedridden, incontinent and requiring constant nursing care and attention.
LACS, lacunar stroke; OCSP, Oxfordshire Community Stroke Project; PACS, partial anterior circulation stroke; POCS, posterior circulation stroke; TACS, total anterior circulation stroke.
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or warfarin at all follow-up time points. For ischaemic stroke, at
no time point was there a statistically signiﬁcant difference
between any drug type compared with no prior treatment.
For ischaemic stroke, the risk of mortality by prior use of AP/
AC is shown in table 3 at various time intervals (0e7 days,
0e30 days, 0e60 days, 0e90 days and 0e365 days). At no time
point was there a statistically signiﬁcant difference between
each type of drug compared with no prior treatment. The risk of
mortality by prior use of aspirin and warfarin in haemorrhagic
stroke is shown in table 4. At all time points evaluated, the use
of warfarin was associated with a statistically signiﬁcant risk of
mortality compared with no therapy. The risk was highest in
the immediate post-stroke period up to 60 days, although similar
ORs were observed at all time points, with all point estimates
showing a greater than 2.3-fold increase in the odds of dying for
prior warfarin use compared with no therapy using the fully
adjusted model (model C). A similar pattern was observed for
aspirin between 1 and 3 months post stroke (30, 60 and 90 days).
We present the discharge AP/AC medications based on prior
use of these medication for ischaemic and haemorrhagic stroke
in online supplementary tables 1 and 2, respectively. Repeating
the analyses adjusting for discharge AP/AC medication for those
who were discharged alive did not alter the results for those
with ischaemic stroke (online supplementary table 3).
We excluded 323 patients who did not have radiological
conﬁrmation of stroke diagnosis because these patients were
extremely unwell and the clinicians chose palliation (supportive
care only) without further radiological investigation. There was
a 98% mortality rate among these patients. Repeating the
analyses after including them based on clinical diagnosis did not
alter the results (data not shown).
DISCUSSION
This study showed no evidence that short, medium or longer
term mortality (up to 1 year) post stroke was inﬂuenced by prior
AP/AC therapy in patients who had ischaemic stroke. However,
in patients with haemorrhagic stroke, prior use of warfarin poses
a signiﬁcantly increased risk of mortality at all time points
examined. Prior use of aspirin therapy also appears to carry
a higher risk compared with no therapy at 30, 60 and 90 days in
this group.
Our results suggest that there is an increase in early mortality
(within 7 and 30 days) for haemorrhagic stroke associated with
warfarin therapy. Previous studies of patients on aspirin therapy
prior to intracranial haemorrhage found similar poor short-term
outcomes and increased mortality, and suggested that it may be
related to haematoma growth in patients on AP therapy.12 13
However there are other studies suggesting that AP medication
at the onset of intracerebral haemorrhage is not associated with
an increase in haemorrhage volume, haemorrhage expansion and
clinical outcome at 90 days.14 An ongoing clinical trial is
exploring the potential beneﬁt of platelet transfusion in patients
with prior AP therapy and intracerebral haemorrhage.15
To our knowledge, this is the ﬁrst study to report the effects
of prior AP/AC treatment on mortality at different time points
for both short (7 and 30 days), medium (60 and 90 days) and
longer-term follow-up (365 days) after hospital admission with
acute ischaemic or haemorrhagic stroke. While Thompson and
colleagues previously reported that AP use was associated with
an increased risk of mortality in haemorrhagic stroke in their
meta-analysis up to 90 days post stroke,8 we have furthered
their observations in that prior warfarin use also increases
the risk of mortality post haemorrhagic stroke up to 1-year
Table 2 Mortality of patients between different time points
Time points
Ischaemic stroke Haemorrhagic stroke
No.
at risk
No.
deaths (%)
Risk of
mortality (chance
in 1000)/day
Cumulative mortality
function (%) (95% CI)
No.
at risk
No.
deaths (%)
Risk of
mortality (chance
in 1000)/day
Cumulative
mortality function
(%) (95% CI)
p Value
(Ischaemic vs
haemorrhagic)
0e7 days 2838 201 (7) 10.1 7.1 (6.2 to 8.1) 470 122 (26) 37.1 26.0 (22.2 to 30.2) <0.0001
8e30 days 2637 285 (11) 15.4 17.1 (15.8 to 18.6) 348 55 (16) 22.6 37.7 (33.5 to 42.2) 0.0040
31e60 days 2352 160 (7) 9.7 22.8 (21.3 to 24.4) 293 22 (8) 10.7 42.3 (38.0 to 46.9) 0.7812
61e90 days 2192 71 (3) 4.6 25.3 (23.7 to 26.9) 271 6 (2) 3.2 43.6 (39.3 to 48.2) 0.3182
91e365 days 2121 282 (13) 19.0 35.2 (33.5 to 37.0) 265 22 (8) 11.9 48.3 (43.9 to 52.9) 0.0153
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Figure 1 KaplaneMeier survival estimates for patients with haemor-
rhagic stroke by prior antiplatelet or anticoagulant use.
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Figure 2 KaplaneMeier survival estimates for patients with ischaemic
stroke by prior antiplatelet or anticoagulant use.
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follow-up. We also found that the increased mortality risk in
haemorrhagic stroke with the prior use of aspirin occurred at 30-
day and 90-day follow-up.
As a hospital-register-based study, we are not able to assess the
beneﬁt of use of warfarin to prevent ischaemic stroke at the
population level. It is well known that warfarin use has an
overall beneﬁcial effect in preventing ischaemic stroke in those
with atrial ﬁbrillation at the expense of higher risk of major
bleeding, including haemorrhagic stroke.16 17 Understanding the
likelihood of mortality at different time points based on
different stroke types and prior use of AP/AC has clinical prog-
nostic value. This information can be considered in conjunction
with other risk factors for mortality to help patients, families
and clinicians to decide on treatment options and appropriate
care.18 One recent study evaluated stroke incidence and death
rates using the Ludwigshafen Stroke Register.19 This study
reported ﬁrst-ever stroke death rates of 13.6%, 16.4% and 23.3%
at 28, 90 and 365 days, respectively. Compared with these
results, there were more cases of stroke and higher rates of
mortality in the current study (20% at 30 days, 28% at 90 days
and 37% at 365 days). The reasons for the difference may be
because we did not exclude patients who had previous stroke
and our data are based on hospitalised strokes only. Further, we
do not have data on indication of AP/AC use prior to stroke or
cause of death.
Our results are different in some respects to previously
reported studies evaluating the impact of pre-admission AP/AC
therapy in both ischaemic and haemorrhagic stroke.5e8 20 21 Our
study has a much longer follow-up of up to 1 year post event.
Furthermore, to date most studies focused on evaluating func-
tional outcomes and stroke severity instead of mortality. Our
study also examined ischaemic and haemorrhagic stroke
whereas most other studies only focused on one type of stroke.
Ideally antithrombotic treatment following the index stroke also
needs to be considered. Although we collected the data on AP/
AC medication at discharge, we were not able to take this into
account because discharge AP/AC therapy is dependent on the
prior use of these agents (co-linearity issue).
We were not able to explore the mechanism that AP/AC
therapy might increase the risk of mortality in haemorrhagic
stroke and the mechanisms remain unclear. The severity of the
vascular event depends on the type of vascular insult and the
patient’s response to it, which may affect the development and
expansion of haematoma and underlying co-pathology.
However, previous studies show conﬂicting results. Some
studies suggest that prior AP agents are associated with
increased haematoma growth22 and mortality,23 while another
study suggests that they do not affect haemorrhage growth or
outcome after intracranial haemorrhage.14 This may be because
patients’ response to brain injury and mortality are likely to be
inﬂuenced by multiple factors.
The strengths of our study include the large sample size and
the fact that the data were collected prospectively. Furthermore,
because the UK has a NHS which provides primary (general or
Table 3 ORs (95% CIs) of mortality post ischaemic stroke based on prior therapy
Mortality Unadjusted Model A Model B Model C
0e7 days, N 2838 2838 2654 2530
No therapy* 1.00 1.00 1.00 1.00
Aspirin 1.07 (0.78 to 1.46) 0.99 (0.73 to 1.36) 1.05 (0.74 to 1.48) 0.92 (0.64 to 1.34)
Aspirin plus dipyridamole 1.03 (0.44 to 2.41) 0.95 (0.40 to 2.23) 1.18 (0.50 to 2.83) 0.94 (0.38 to 2.37)
Clopidogrel 0.93 (0.33 to 2.61) 0.96 (0.34 to 2.71) 1.26 (0.44 to 3.59) 1.79 (0.59 to 5.45)
Warfarin 1.32 (0.77 to 2.30) 1.29 (0.74 to 2.25) 1.28 (0.69 to 2.38) 1.40 (0.72 to 2.72)
0e30 days, N 2838 2838 2654 2530
No therapy* 1.00 1.00 1.00 1.00
Aspirin 1.18 (0.96 to 1.46) 1.05 (0.85 to 1.30) 1.01 (0.80 to 1.28) 0.90 (0.70 to 1.17)
Aspirin plus dipyridamole 0.84 (0.45 to 1.57) 0.73 (0.39 to 1.38) 0.75 (0.38 to 1.47) 0.60 (0.29 to 1.26)
Clopidogrel 0.98 (0.49 to 1.94) 1.05 (0.52 to 2.13) 1.17 (0.56 to 2.48) 1.67 (0.75 to 3.71)
Warfarin 1.15 (0.77 to 1.72) 1.09 (0.73 to 1.65) 1.02 (0.65 to 1.60) 0.88 (0.52 to 1.49)
0e60 days, N 2838 2838 2654 2525
No therapy* 1.00 1.00 1.00 1.00
Aspirin 1.18 (0.98 to 1.43) 1.03 (0.85 to 1.26) 1.00 (0.81 to 1.23) 0.90 (0.71 to 1.14)
Aspirin plus dipyridamole 0.77 (0.44 to 1.37) 0.66 (0.37 to 1.18) 0.69 (0.38 to 1.28) 0.55 (0.28 to 1.09)
Clopidogrel 1.04 (0.57 to 1.92) 1.15 (0.61 to 2.16) 1.07 (0.53 to 2.15) 1.49 (0.70 to 3.16)
Warfarin 1.32 (0.93 to 1.88) 1.25 (0.87 to 1.79) 1.23 (0.83 to 1.82) 1.20 (0.76 to 1.89)
0e90 days, N 2838 2838 2654 2525
No therapy* 1.00 1.00 1.00 1.00
Aspirin 1.18 (0.98 to 1.42) 1.02 (0.85 to 1.24) 0.99 (0.80 to 1.21) 0.90 (0.72 to 1.14)
Aspirin plus dipyridamole 0.79 (0.46 to 1.36) 0.66 (0.38 to 1.16) 0.71 (0.40 to 1.28) 0.58 (0.30 to 1.12)
Clopidogrel 1.09 (0.61 to 1.94) 1.21 (0.66 to 2.21) 1.17 (0.60 to 2.26) 1.64 (0.80 to 3.34)
Warfarin 1.40 (1.00 to 1.96) 1.31 (0.93 to 1.86) 1.26 (0.86 to 1.85) 1.28 (0.82 to 1.98)
0e365 days, N 2838 2838 2654 2525
No therapy* 1.00 1.00 1.00 1.00
Aspirin 1.18 (1.00 to 1.40) 1.00 (0.84 to 1.19) 0.96 (0.80 to 1.16) 0.90 (0.73 to 1.10)
Aspirin plus dipyridamole 0.96 (0.60 to 1.52) 0.78 (0.48 to 1.27) 0.81 (0.49 to 1.35) 0.66 (0.37 to 1.17)
Clopidogrel 1.06 (0.63 to 1.80) 1.20 (0.68 to 2.10) 1.10 (0.60 to 2.02) 1.45 (0.75 to 2.78)
Warfarin 1.22 (0.89 to 1.68) 1.10 (0.79 to 1.54) 1.10 (0.77 to 1.58) 1.06 (0.71 to 1.59)
Model A: adjusted for age, age squared, and gender.
Model B: adjusted for age, age squared, gender and premorbid Rankin score.
Model C: adjusted for age, age squared, gender, premorbid Rankin score and Oxfordshire Community Stroke Project (OCSP) stroke
type.
*Reference category.
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family practice), and secondary and tertiary care (hospital
medicine) the PAS is a reliable method of mortality ascertain-
ment. We were also able to make adjustments for age, gender,
premorbid Rankin score and OCSP classiﬁcation of stroke,
which are important prognostic indicators of mortality.
Premorbid Rankin score10 and OCSP classiﬁcations24 have been
shown to be major determinants of mortality in stroke.
Our study has limitations. As we used the hospital-based
register data some cases of stroke might not have been included,
such as patients managed in the community or those who died
before admission. Nevertheless, for hospital-based practicing
physicians our results may be more generalisable for their
patient population. The stroke onset and the time and date of
admission may not be exactly the same (usually a couple of
hours’ difference). However, in a study like ours, with the
primary aim of examining the short-term and longer-term
outcome with usual clinical reference time points, this will not
have an impact on the study ﬁndings. Any outlier effect would
also be attenuated in a study of such a sample size. The nature
of this study is retrospective but identiﬁcation of patients and
data collection occurred prospectively. The stroke severity at
onset (eg, National Institutes of Health Stroke Scale (NIHSS)
score) is not available. However, we were able to adjust for
OCSP, which is indicative of level of stroke severity. Also, we
were unable to consider the management patients received after
admission. We are not able to quantify the effect of level of AC
control (indicated by international normalized ratio (INR)) at
the time of stroke onset. It is possible that higher mortality
associated with prior use of warfarin in people with haemor-
rhagic stroke may be solely attributed to cases with higher than
the therapeutic range of INR. Another limitation was the small
sample size in subsidiary analyses. We also lacked the dose,
duration and indication for the use of AP/AC drugs. Combina-
tions of AP and AC treatment were possible but this is not
usually recommended in the UK. There is a possibility of over-
the-counter aspirin use, which was not captured in the medical
records, resulting in misclassiﬁcation of some aspirin users as
non-users. However, this is unlikely to produce a different
direction of the associations observed. We were unable to explore
cause-speciﬁc mortality, for example cardiovascular versus
cancer mortality. It is unclear whether or not the increased
mortality may be related to initial stroke severity or a comorbid
medical condition associated with antithrombotic use. However,
we adjusted premorbid Rankin score as an indicator of disability,
which is usually related to comorbidity.
It should be noted that the choice of AP/AC in patients who
presented with ischaemic stroke depended on the prior AP/AC
regimen and the aetiology of the stroke (eg, AC for those with
atrial ﬁbrillation). We have presented AP/AC medication use at
the time of hospital discharge for descriptive purposes (see
online supplementary tables). Repeating the analyses adjusting
for discharge AP/AC status did not alter the results. Further, we
were not able to examine the impact of AP/AC use or AC control
immediately after stroke, which may have an impact on short-
term and longer-term outcomes and the potential confounding
effect cannot be excluded.
Future studies should explore whether the adverse effects of
ACs are related to a higher than therapeutic INR level at the time
of the stroke. A previous study found that patients taking
warfarin on admission with intracranial haemorrhage had double
the rate of mortality in a dose-dependent manner.25 While some
studies support the reversal of coagulopathy on admissions with
haemorrhagic stroke,26 27 another study suggests that correction
of INR does not prevent disease progression.28 A study which
evaluated various methods to reverse the coagulopathy concluded
that randomised trials are required to determine the most effec-
tive acute treatment for lasting INR reversal because raised INR
was associated with haematoma enlargement.25 There is
currently a randomised controlled trial underway evaluating the
use of platelet transfusion in acute intracerebral haemorrhage.29
Whether post-stroke AP/AC choice has an impact on outcome
(particularly for ischaemic stroke) requires further evaluation.
Table 4 ORs (95% CIs) of mortality post haemorrhagic stroke based on prior therapy
Mortality Unadjusted Model A Model B Model C
0e7 days, N 451 451 414 333
No therapyy 1.00 1.00 1.00 1.00
Aspirin 0.99 (0.60 to 1.62) 1.03 (0.62 to 1.71) 1.24 (0.73 to 2.12) 1.31 (0.64 to 2.68)
Warfarin 2.06 (1.13 to 3.79)** 2.13 (1.15 to 3.96)** 2.02 (1.04 to 3.89)** 2.91 (1.23 to 6.89)**
0e30 days, N 451 451 414 378
No therapyy 1.00 1.00 1.00 1.00
Aspirin 1.62 (1.05 to 2.50)** 1.46 (0.93 to 2.29) 1.70 (1.05 to 2.74)** 2.36 (1.18 to 4.71)**
Warfarin 1.83 (1.02 to 3.28)** 1.76 (0.97 to 3.21) 1.79 (0.95 to 3.38) 2.37 (1.00 to 5.61)**
0e60 days, N 451 451 417 380
No therapyy 1.00 1.00 1.00 1.00
Aspirin 1.62 (1.06 to 2.48)** 1.40 (0.90 to 2.19) 1.63 (1.02 to 2.61)** 2.18 (1.10 to 4.29)**
Warfarin 2.02 (1.13 to 3.61)** 1.90 (1.04 to 3.46)** 2.07 (1.10 to 3.89)** 2.86 (1.20 to 6.84)**
0e90 days, N 451 451 417 380
No therapyy 1.00 1.00 1.00 1.00
Aspirin 1.80 (1.18 to 2.75)* 1.54 (0.99 to 2.40) 1.83 (1.14 to 2.93)** 2.56 (1.27 to 5.13)*
Warfarin 1.99 (1.11 to 3.55)** 1.85 (1.02 to 3.37)** 2.02 (1.08 to 3.81)** 2.82 (1.16 to 6.86)**
0e365 days, N 451 451 417 380
No therapyy 1.00 1.00 1.00 1.00
Aspirin 1.71 (1.12 to 2.61)** 1.36 (0.86 to 2.13) 1.57 (0.98 to 2.54) 1.67 (0.89 to 3.12)
Warfarin 1.87 (1.04 to 3.34)** 1.67 (0.91 to 3.08) 1.89 (1.00 to 3.59) 2.44 (1.06 to 5.62)**
Model A: adjusted for age, age squared and gender.
Model B: adjusted for age, age squared, gender and premorbid Rankin score.
Model C: adjusted for age, age squared, gender, premorbid Rankin score and Oxfordshire Community Stroke Project (OCSP) stroke
type.
*p<0.05, **p<0.01.
yReference category.
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In summary, we found that prior AP/AC use did not affect
mortality after ischaemic stroke. Our study conﬁrmed the worse
mortality outcome associated with prior aspirin use and high-
lighted the potential adverse impact of prior warfarin use on
mortality in haemorrhagic stroke. Predictors of poor prognosis in
patients with prior AP/AC therapy need further investigation.
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Key messages
< Prior antiplatelet or anticoagulant use was associated with
increased mortality following haemorrhagic stoke but not
ischaemic stroke after adjustment for common factors
associated with a poor prognosis.
< The reasons for this poor prognosis and potential therapeutic
options need exploring in future studies.
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